首页|Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
Therapeutic potential of targeting cathepsin S in pulmonary fibrosis
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Cathepsin S (CTSS)， a lysosomal protease， belongs to a family of cysteine cathepsin proteases that promote degradation of damaged proteins in the endolysosomal pathway。 Aberrant CTSS expression and regulation are associated with the pathogenesis of several diseases， including lung diseases。 CTSS overexpression causes a variety of pathological processes， including pulmonary fibrosis， with increased CTSS secretion and accelerated extracellular matrix remodeling。 Compared to many other cysteine cathepsin family members， CTSS has unique features that it presents limited tissue expression and retains its enzymatic activity at a neutral pH， suggesting its decisive involvement in disease microenvironments。 In this review， we investigated the role of CTSS in lung disease， exploring recent studies that have indicated that CTSS mediates fibrosis in unique ways， along with its structure， substrates， and distinct regulation。 We also outlined examples of CTSS inhibitors in clinical and pre-clinical development and proposed CTSS as a potential therapeutic target for pulmonary fibrosis。
Cathepsin SPulmonary fibrosisTherapeutic targetInhibitorsClinical and preclinical
YoungJo Yoo、Eun Choi、Yejin Kim、Yunyoung Cha、Eunhye Um、Younghwa Kim、Yunji Kim、Yun-Sil Lee
展开 >
Graduate School of Pharmaceutical Sciences and College of Pharmacy, Ewha Womans University, Seoul
NSTL
